Stoke Therapeutics, Inc. Overview
Pro stress-test →Stoke Therapeutics is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to develop antisense oligonucleotides (ASOs) to selectively restore protein levels. The company's first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.
Strategic Profile
Pro stress-test →Stoke has obtained regulatory designations for zorevunersen including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, and maintains a strategic collaboration with Biogen under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights. The company is pursuing treatment for autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.
Competitive Landscape
Pro stress-test →Stoke operates in the RNA therapeutics space targeting rare genetic diseases where few treatment options exist. Competitors include other antisense and gene therapy platforms, but Stoke's differentiated TANGO approach targeting haploinsufficiency diseases provides competitive positioning in underserved neurological and ophthalmic markets.
Industry Context
Stoke Therapeutics, Inc. operates in Biopharmaceuticals - RNA Therapeutics & Rare Genetic Diseases.
Key facts
Founded: 2014 · Headquarters: Bedford, Massachusetts, United States · Revenue: $36.56M (2024)